10-K: QHSLab posts 2025 profit, slashes debt

QHSLab delivered 26% revenue growth, positive net income, and eliminated over $1.4M of defaulted convertibles via repurchase, while warning of going-concern risks and material control weaknesses.

Summary

• Revenue rose 26.2% to $2,691,741 in 2025 (2024: $2,131,926), led by Integrated Service Program (ISP) revenue up 74.3% to $1,121,134.
• Gross profit increased to $1,810,849 with gross margin expanding to 67.3% (2024: 63.7%) as mix shifted toward ISP services and costs improved after the MedScience asset acquisition.
• Net income was $457,417 (2024: net loss of $259,239), primarily driven by a net gain on extinguishment of debt and related items; operating income was $131,244 (2024: $205,738).
• Interest expense declined to $237,413 (2024: $465,055) after debt reductions; a $665,755 net gain on extinguishment of debt and a $102,251 loss on conversion were recorded.
• Cash increased to $636,157 (Dec 31, 2024: $157,168); working capital improved to $433,149 (from a deficit of $1,986,481).
• Convertible notes payable dropped to $20,000 (from $1,284,147) following a $300,000 repurchase that extinguished $1,445,695 of defaulted notes (principal and accrued interest).
• A MedScience promissory note with $470,529 outstanding was settled via 1,568,432 common shares, removing the liability.
• 2025 capital raise: $499,998 via private placement (1,666,663 common shares at $0.30 and 416,666 warrants at $0.60, expiring Dec 31, 2030).
• Shares outstanding were 15,032,788 as of March 30, 2026; preferred outstanding: Series A 1,080,092 and Series A-2 2,644,424.
• Auditor included a going-concern emphasis; management disclosed material weaknesses in internal controls (segregation of duties, lack of experienced accounting personnel).

Sentiment

Score: 6

Explanation: StockSavvy.ai views the combination of strong revenue growth, margin expansion, and significant deleveraging as moderately positive, tempered by going-concern warnings, internal control weaknesses, dilution, and reliance on non-recurring gains.

Positives

• Top-line momentum: revenue up 26.2% to $2.69M; ISP revenue up 74.3% to $1.12M, signaling traction in recurring digital workflows.
• Margin expansion: gross margin improved to 67.3% (from 63.7%), reflecting favorable mix and cost synergies.
• Balance sheet reset: convertible notes reduced to $20,000 from $1.28M after a $300,000 repurchase retired $1.45M of defaulted notes.
• Liquidity and equity turnaround: cash rose to $636k; working capital swung to +$433k; stockholders’ equity improved to $1.62M from a $(0.61)M deficit.
• Interest burden eased: interest expense fell to $237k (from $465k), with management expecting lower interest until new debt is taken on.

Negatives

• Profit quality: 2025 net income ($457k) was largely non-recurring, driven by a net gain on extinguishment of debt; operating income fell to $131k (from $206k).
• Going-concern risk persists per auditor and management disclosures despite recent improvements.
• Internal control material weaknesses remain (segregation of duties; limited accounting personnel), and disclosure controls were deemed ineffective as of Dec 31, 2025.
• Customer concentration in receivables (two customers represented 16.7% and 10.2% of A/R at year-end).
• Dilution from share issuances to settle debt (1,568,432 shares) and to raise capital (1,666,663 shares), with additional dilution risk from preferred shares and warrants.

Risks

• Sustaining profitability and going-concern risk: prior losses, modest revenue base ($2.69M), and reliance on non-recurring debt gains raise uncertainty about ongoing profitability and liquidity.
• Need for additional financing to fund growth; inability to obtain capital on acceptable terms could restrict operations and dilute shareholders.
• Material weaknesses in internal controls (segregation of duties; lack of experienced accounting personnel) may impair timely and accurate reporting.
• Revenue concentration in limited product lines and dependence on third parties for AllergiEnd products could materially impact results if supply is disrupted.
• Regulatory exposure: extensive healthcare, privacy (HIPAA), anti-kickback, Stark Law, and FDA mobile app guidance may impact operations, with potential civil/criminal penalties for non-compliance.
• Cybersecurity and data privacy risks related to storage and transmission of PHI, including third-party vendor exposure and potential litigation and remediation costs.
• Competitive pressures from larger, better-capitalized digital health and allergy diagnostics players could limit market share and pricing power.
• Penny stock volatility, limited liquidity on OTCQB, and significant control by the sole director/officer may depress stock price and deter acquisitions.
• Potential dilution from authorized share capacity (900M common authorized) and outstanding preferred stock with voting and conversion rights (Series A and A-2).

Future Outlook

Management focuses on expanding adoption among independent primary care practices, increasing patient enrollment per practice, and deepening recurring ISP workflows. Longer-term opportunities include adding clinical domains, tighter EHR workflow integration, and strategic partnerships, subject to capital availability and regulatory considerations. Interest expense is expected to remain lower absent new debt.

Management Comments

• Plans to grow recurring ISP revenue by onboarding more independent primary care practices and increasing utilization per practice.
• Expects R&D and sales investments to continue as QHSLab expands feature sets and commercialization.
• Notes interest expense should remain lower following debt extinguishment until additional borrowing is undertaken.
• Acknowledges material weaknesses in internal controls and intends to add personnel and strengthen review procedures as cash flow permits.
• Emphasizes a capital-efficient sales strategy that limits customization and leverages existing relationships and referrals.

Industry Context

StockSavvy.ai notes that primary care is shifting toward preventive, digital, and reimbursable non-face-to-face care. Shortages in behavioral health and allergy specialists create openings for scalable screening and care-management SaaS like QHSLab. However, competition from larger digital health platforms and EHR-integrated tools is intense, and payer documentation requirements can slow adoption.

Comparison to Industry Standards

• Scale: With $2.7M revenue, QHSLab is micro-scale versus Teladoc Health (~$2B+ revenue) and Amwell (~$1B-). Scale limits sales leverage and R&D velocity relative to peers.
• Margins: A 67% gross margin is within or above many healthcare SaaS peers (e.g., Phreesia mid-60% range historically), indicating attractive unit economics if growth sustains.
• Profit quality: Positive net income driven by one-offs contrasts with mature peers that target sustainable operating profitability; recurring operating margin remains thin.
• Balance sheet: Deleveraging and equity swing to positive is favorable for a microcap; larger peers typically rely less on punitive convertible structures.
• Product positioning: Focus on behavioral vital signs and allergy within primary care is a niche strategy compared to broad telehealth (Teladoc/Amwell), potentially enabling higher-practice-ROI workflows but facing EHR embedded competition.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal or administrative proceedings were reported.

Related Party Transactions

• Loan due to CEO and principal shareholder: $91,085 outstanding as of December 31, 2025 (10% note maturing March 31, 2027).
• CEO is a shareholder of MedScience; the MedScience acquisition note ($470,529 outstanding) was repurchased and extinguished on December 31, 2025 via issuance of 1,568,432 common shares.

Stakeholder Impact

• Shareholders: Balance sheet de-risked via debt extinguishment, but dilution from equity issuance and debt settlements increased share count.
• Creditors: Holders of defaulted notes received $300,000 cash in repurchase; MedScience received equity, eliminating the payable.
• Customers: Increased ISP investment and platform enhancements may improve service quality and reliability.
• Employees: Headcount at 12 (as of March 30, 2026); ongoing training and cybersecurity practices emphasized; potential future hiring to strengthen controls.
• Preferred holders: Series A-2 dividends satisfied in common shares, contributing to dilution but preserving cash.

Next Steps

• Pursue additional independent primary care practice contracts and increase patient enrollment per practice to grow recurring ISP revenue.
• Continue R&D investment in QHSLab feature expansion and clinical programs.
• Enhance internal controls and consider adding accounting personnel as resources allow.
• Evaluate additional capital options to fund growth initiatives if needed.

Key Dates

Recommendation

The business showed solid revenue growth, margin improvement, and significant deleveraging, but profitability was largely non-recurring, material control weaknesses persist, and going-concern risk remains. A neutral stance is appropriate pending evidence of sustained operating profitability, control remediation, and continued recurring revenue traction.

Keywords

QHSLab, USAQ, digital health, primary care, SaaS, behavioral health screening, AllergiEnd, allergy diagnostics, immunotherapy, integrated service program, convertible notes, debt extinguishment, private placement, OTCQB, HIPAA